SCHEMBL21857732

SCHEMBL21857732

CC1(C)NC(=O)N(c2cnc(Cl)cn2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
AR P10275 10/20 0.45
POLB P06746 1/20 0.34
ALDH1A1 P00352 2/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
SIRT6 Q8N6T7 1/20 0.33
PANK3 Q9H999 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29913457 1.00 AR (0.45) ARPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL21953172 0.86 AR (0.36) ARSIRT6PANK3
SCHEMBL21953171 0.82 FPR2 (0.37) ALDH1A1RAB9APANK3
SCHEMBL31009069 0.82 FPR2 (0.37) ALDH1A1RAB9APANK3
SCHEMBL31657833 0.82 FPR2 (0.37) ALDH1A1RAB9APANK3
SCHEMBL9900172 0.73 AR (0.56) ARPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL21580615 0.73 AR (0.51) ARALDH1A1SMN1; SMN2
SCHEMBL21610251 0.72 AR (0.43) ARPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL31572814 0.71 AR (0.45) ARALDH1A1RAB9ASMN1; SMN2
SCHEMBL1772990 0.70 AR (0.56) ARPOLBRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304564-A1 NOVEL KV3 MODULATORS AUTIFONY THERAPEUTICS LTD (GB) 2025-10-02 US disclosed
US-12358901-B2 KV3 modulators AUTIFONY THERAPEUTICS LIMITED (GB) 2025-07-15 US disclosed
EP-3867247-B1 NOVEL COMPOUNDS AUTIFONY THERAPEUTICS LTD (GB) 2024-07-24 EP disclosed
EP-4100402-A1 KV3 MODULATORS Autifony Therapeutics Limited (GB) 2022-12-14 EP disclosed
CN-115066424-A Kv3 modulators 奥蒂福尼疗法有限公司 2022-09-16 CN disclosed
US-20210276985-A1 NOVEL COMPOUNDS AUTIFONY THERAPEUTICS LIMITED (GB) 2021-09-09 US disclosed
US-20210276985-A1 NOVEL COMPOUNDS AUTIFONY THERAPEUTICS LIMITED (GB) 2021-09-09 US disclosed
WO-2021156584-A1 KV3 MODULATORS AUTIFONY THERAPEUTICS LIMITED (GB) 2021-08-12 WO disclosed
WO-2021156584-A1 KV3 MODULATORS AUTIFONY THERAPEUTICS LIMITED (GB) 2021-08-12 WO disclosed
WO-2020079422-A1 NOVEL COMPOUNDS AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-23 WO disclosed
WO-2020079422-A1 NOVEL COMPOUNDS AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358901-B2 KV3 modulators KCNN3, KCNA3, KCNH3 AR 1889/4885POLB 4639/4885ALDH1A1 3109/4885
US-20210276985-A1 NOVEL COMPOUNDS NR3C2, AKR1C3, MC2R AR 523/4885POLB 4215/4885ALDH1A1 918/4885
US-20250304564-A1 NOVEL KV3 MODULATORS KCNN3, KCNA3, KCND3 AR 2073/4885POLB 4589/4885ALDH1A1 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.